American Gene Technologies says clinical trial shows increases in immunity against HIV

Published on :

ROCKVILLE, Md. (7News) — There’s more good news in the fight to cure HIV.
American Gene Technologies says its clinical trial has resulted in more patients with substantial increases in virus-specific T-cells with immunity against HIV.
Progress in HIV cure: AGT hopes to have a ‘functionally cured patient by next summer’
“Now the question will be the very final step when we withdraw antiretroviral therapy, will it behave as we expect which is to take over viral suppression and these patients will not need to go back on their antiretroviral therapy again,” said CEO Jeff Galvin.
He says that process would start by the end of March at the earliest and he hopes to find out how successful it is by June.

5 Top Maryland Cell and Gene Therapy Companies Actively Searching for Talent

Two businesspeople shaking hands, with logos of Kite Pharma, NextCure, Arcellx, NexImmune, and MaxCyte
Published on :

The BHCR cluster, in particular, includes a host of emerging and established cell and gene therapy companies, as well one of the deepest and most advanced biomanufacturing infrastructures in the U.S. While the cell and gene therapy industry still faces challenges like high manufacturing costs, high cost per dose to patients and complex supply chain issues, this sector remains very healthy and is continuing to grow rapidly in our region and globally.

NeuExcell Therapeutics, Inc. Signs Lease with The Discovery Labs to Establish Corporate Headquarters in the Philadelphia Region

NeuExcell Therapeutics Logo
Published on :

NeuExcell Therapeutics, Inc., a preclinical gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases, today announced the signing of a lease with The Discovery Labs in King of Prussia, PA. This lease sets the stage for NeuExcell to establish their long-term corporate headquarters in the heart of Philadelphia’s Cellicon Valley region and enables the company to build a world-class team tapping into the veteran cell and gene therapy talent in Greater Philadelphia.

REGENXBIO Closes $370M+ Gene Therapy Eye Care Collaboration Agreement with AbbVie for Wet AMD and Diabetic Retinopathy

Published on :

REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.

REGENXBIO and Solid Biosciences Take Aim at Rare Diseases with AAV Gene Therapies via New Pathway Development Consortium

REGENXBIO Logo
Published on :

Rare disease specialist REGENXBIO is partnering with Solid Biosciences to advance AAV gene therapies for rare diseases through an accelerated approval pathway with the U.S. Food and Drug Administration.

Spark signs gene therapy licensing deal valued at up to $328.5M

Published on :

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark with the exclusive, worldwide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the preclinical program in collaboration with Spark.

AbbVie and Rockville’s REGENXBIO Announce Eye Care Collaboration

Published on :

AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise. Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. REGENXBIO to receive $370 million upfront payment

American Gene Technologies HIV Cure Program Releases Initial Clinical Trial Data

Published on :

American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease, is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells. The cells are collected by leukapheresis, modified outside the body, then re-infused. Once infused, the cells are expected to durably suppress the virus at undetectable levels without the need for antiretroviral treatment.